CEP-1347 (Cephalon Inc.) is a 5,16-bis[(ethylthio)methyl] derivative of indolocar-bazole, k252a, that is being tested for neurodegenerative diseases, including PD. The drug inhibits proteins in the mixed lineage kinase family (32,33). These proteins activate c-Jun N-terminal kinase, which is a key kinase in the stress-activated protein kinase pathway. Therefore, the drug is thought to inhibit programmed cell death. Two 28-day trials in PD did not show any symptomatic clinical effect or change on
[123I] B-CIT SPECT and an interim analysis of a large multicenter trial indicated that the trial was unlikely to demonstrate evidence of a significant effect leading to Cephalon's discontinuation of the study (34).
Was this article helpful?